AR007059A1 - Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto - Google Patents
Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contactoInfo
- Publication number
- AR007059A1 AR007059A1 ARP970101925A ARP970101925A AR007059A1 AR 007059 A1 AR007059 A1 AR 007059A1 AR P970101925 A ARP970101925 A AR P970101925A AR P970101925 A ARP970101925 A AR P970101925A AR 007059 A1 AR007059 A1 AR 007059A1
- Authority
- AR
- Argentina
- Prior art keywords
- interferon
- contact
- medicines
- preparation
- compositions via
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
Abstract
El uso de interferón para preparar un medicamento o una composición que contiene una cantidad terapéuticamente efectiva de un interferón adaptada parael contacto oromucosal para tratar una enfermedad neoplásica en mamíferos . La cantidad deinte rferón administrado es menor que la cantidad que induce unarespuesta patológica cuando es administrada parenteralmente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPN9765A AUPN976596A0 (en) | 1996-05-09 | 1996-05-09 | Stimulation of host defence mechanisms |
Publications (1)
Publication Number | Publication Date |
---|---|
AR007059A1 true AR007059A1 (es) | 1999-10-13 |
Family
ID=3794078
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970101924A AR007058A1 (es) | 1996-05-09 | 1997-05-08 | Uso de interferon en medicamentos y composiciones para contacto oromucosal |
ARP970101925A AR007059A1 (es) | 1996-05-09 | 1997-05-08 | Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970101924A AR007058A1 (es) | 1996-05-09 | 1997-05-08 | Uso de interferon en medicamentos y composiciones para contacto oromucosal |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP0956040B1 (es) |
JP (2) | JP3806444B2 (es) |
KR (2) | KR100399499B1 (es) |
CN (1) | CN1154508C (es) |
AR (2) | AR007058A1 (es) |
AT (2) | ATE316793T1 (es) |
AU (3) | AUPN976596A0 (es) |
BR (2) | BR9709066A (es) |
CA (2) | CA2253908A1 (es) |
DE (2) | DE69735204T2 (es) |
ES (2) | ES2260790T3 (es) |
ID (2) | ID16885A (es) |
IL (2) | IL126972A0 (es) |
NZ (2) | NZ332688A (es) |
TW (1) | TW528599B (es) |
WO (2) | WO1997041883A1 (es) |
ZA (1) | ZA973988B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6299871B1 (en) * | 1998-07-24 | 2001-10-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases |
US6710025B1 (en) | 1999-05-26 | 2004-03-23 | The Brigham And Women's Hospital, Inc. | Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin |
WO2000071148A2 (en) * | 1999-05-26 | 2000-11-30 | The Brigham And Women's Hospital, Inc. | Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin |
US20040258663A1 (en) * | 2003-05-08 | 2004-12-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon alpha |
DE602005002673T2 (de) | 2004-04-29 | 2008-07-24 | F. Hoffmann-La Roche Ag | Nukleotidsequenzvariation im Gen NS5A als Marker |
DE102007014752A1 (de) | 2007-03-28 | 2008-10-02 | Dusek, Niels, Dr. | Verwendung von humanidentischem oder humanaequivalentem rekombinantem Interleukin-2 (heqlL-2) als Therapeutikum in der Human- und Veterinärmedizin |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1982000588A1 (en) * | 1980-08-22 | 1982-03-04 | Illinois Univ | Delivery of biologically active components of heterologous species interferon isolates |
US5286748A (en) * | 1981-01-05 | 1994-02-15 | Eby Iii George A | General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity |
US4820515A (en) * | 1982-12-13 | 1989-04-11 | Texas A&M University System | Method of using interferon in low dosage to regulate appetite and efficiency of food utilization |
US4605555A (en) * | 1984-09-20 | 1986-08-12 | Sun Star Kabushiki Kaisha | Composition and method for treating keratosic disorder of skin and mucosa |
IL76591A0 (en) * | 1984-10-05 | 1986-02-28 | Bioferon Biochem Substanz | Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof |
ZA878295B (en) * | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
JP2704546B2 (ja) * | 1989-04-04 | 1998-01-26 | 光利 太良 | Atll治療用吸入剤 |
US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5215741A (en) * | 1990-10-30 | 1993-06-01 | Amarillo Cell Culture Company, Incorporated | Method for prevention of parasite infections |
MX9102512A (es) * | 1990-12-14 | 1992-06-01 | Schering Corp | Administracion oral de interferon alfa en el tratamiento de enfermedades del pulmon. |
US5780021A (en) * | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
IL113280A (en) * | 1994-04-12 | 2004-12-15 | Res Dev Foundation | A preparation for the treatment of self-immunization diseases with the help of interferon of one type |
ATE316792T1 (de) * | 1996-05-09 | 2006-02-15 | Pharma Pacific Pty Ltd | Stimulierung wirtseigener abwehrmechanismen gegen krebs |
-
1996
- 1996-05-09 AU AUPN9765A patent/AUPN976596A0/en not_active Abandoned
-
1997
- 1997-05-05 KR KR10-1998-0709024A patent/KR100399499B1/ko not_active IP Right Cessation
- 1997-05-05 IL IL12697297A patent/IL126972A0/xx unknown
- 1997-05-05 BR BR9709066-2A patent/BR9709066A/pt not_active IP Right Cessation
- 1997-05-05 NZ NZ332688A patent/NZ332688A/xx unknown
- 1997-05-05 EP EP97919563A patent/EP0956040B1/en not_active Expired - Lifetime
- 1997-05-05 JP JP53969597A patent/JP3806444B2/ja not_active Expired - Fee Related
- 1997-05-05 WO PCT/IB1997/000489 patent/WO1997041883A1/en active IP Right Grant
- 1997-05-05 DE DE69735204T patent/DE69735204T2/de not_active Expired - Fee Related
- 1997-05-05 AU AU23992/97A patent/AU729514B2/en not_active Ceased
- 1997-05-05 KR KR10-1998-0709026A patent/KR100399501B1/ko not_active IP Right Cessation
- 1997-05-05 AU AU27109/97A patent/AU724190B2/en not_active Ceased
- 1997-05-05 CN CNB971945047A patent/CN1154508C/zh not_active Expired - Fee Related
- 1997-05-05 JP JP53970397A patent/JP3806446B2/ja not_active Expired - Fee Related
- 1997-05-05 IL IL12697097A patent/IL126970A0/xx not_active IP Right Cessation
- 1997-05-05 BR BR9709223-1A patent/BR9709223A/pt not_active Application Discontinuation
- 1997-05-05 ES ES97919563T patent/ES2260790T3/es not_active Expired - Lifetime
- 1997-05-05 CA CA002253908A patent/CA2253908A1/en not_active Abandoned
- 1997-05-05 AT AT97919563T patent/ATE316793T1/de not_active IP Right Cessation
- 1997-05-05 ES ES97920907T patent/ES2260794T3/es not_active Expired - Lifetime
- 1997-05-05 NZ NZ332690A patent/NZ332690A/xx unknown
- 1997-05-05 CA CA002253902A patent/CA2253902A1/en not_active Abandoned
- 1997-05-05 AT AT97920907T patent/ATE316791T1/de not_active IP Right Cessation
- 1997-05-05 DE DE69735201T patent/DE69735201T2/de not_active Expired - Fee Related
- 1997-05-05 WO PCT/IB1997/000594 patent/WO1997041886A1/en active IP Right Grant
- 1997-05-05 EP EP97920907A patent/EP0898478B1/en not_active Expired - Lifetime
- 1997-05-07 TW TW086106145A patent/TW528599B/zh not_active IP Right Cessation
- 1997-05-08 AR ARP970101924A patent/AR007058A1/es unknown
- 1997-05-08 AR ARP970101925A patent/AR007059A1/es unknown
- 1997-05-08 ZA ZA973988A patent/ZA973988B/xx unknown
- 1997-05-09 ID IDP971536A patent/ID16885A/id unknown
- 1997-05-09 ID IDP971537A patent/ID16886A/id unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2172654T3 (es) | Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe. | |
EP0552256A4 (es) | ||
CO4970691A1 (es) | Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica | |
DK0600079T3 (da) | Oral 1alpha-hydroxyprævitamin D | |
BR9807577A (pt) | Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição | |
BRPI0410260A (pt) | composição conjugada para medicamento | |
BR0107869A (pt) | Composições farmacêuticas eletrogiradas | |
ES2055845T3 (es) | Composicion farmaceutica para el tratamiento de la osteoporosis. | |
MX9204268A (es) | Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma. | |
BR9913945A (pt) | Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos | |
HK1030157A1 (en) | Use of consensus interferon and compositions comprising consensus interferon. | |
DK0470117T3 (da) | Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner | |
BR9916114A (pt) | Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina | |
PT1001802E (pt) | Preparacao farmaceutica combinada compreendendo a hormona da paratiroide e um inibidor de reabsorcao ossea | |
AU7284098A (en) | Method for preventing gastritis using amylin or amylin agonists | |
AR007059A1 (es) | Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto | |
ES2177024T3 (es) | Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer. | |
KR910009267A (ko) | 우울증의 치료방법 | |
BR9106272A (pt) | Composicoes farmaceuticas contendo ipriflavona,processo para sua preparacao e uso terapeutico relativo | |
ES2181915T3 (es) | Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones. | |
KR940701249A (ko) | 진통제 | |
AR059965A2 (es) | Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante | |
ES2086536T3 (es) | Uso de ketorolaco para el tratamiento de la enfermedad periodontal. | |
FI945446A (fi) | Kotiinin käyttö tupakan vieroitusoireyhtymän lievittämiseksi | |
ES2101311T3 (es) | Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer. |